Core Points - On October 29, TianKang's stock rose by 1.40%, with a trading volume of 143 million yuan [1] - The financing data shows that on the same day, TianKang had a financing purchase amount of 18.82 million yuan and a net financing purchase of 1.5 million yuan [1] - As of October 29, the total financing and securities lending balance for TianKang was 999.7 million yuan, which is 7.34% of its market capitalization [1] Financing Overview - On October 29, TianKang's financing purchase was 18.82 million yuan, with a current financing balance of 999.7 million yuan, exceeding the 90th percentile level over the past year [1] - The securities lending data indicates that there were no shares sold or repaid on October 29, with a securities lending balance of 0.00 yuan, also exceeding the 80th percentile level over the past year [1] Company Profile - Guangdong TianKang Pharmaceutical Co., Ltd. was established on January 22, 1999, and listed on March 29, 2022 [1] - The company's main business includes the operation, research and development, production, and sales of pharmaceutical products, medical devices, and health materials, along with providing pharmaceutical technology services and technology transfer [1] - The revenue composition of TianKang includes gastrointestinal drugs (32.62%), ophthalmic drugs (25.05%), traditional Chinese medicine and external drugs (21.08%), and sexual health drugs (21.06%) [1] Financial Performance - As of September 30, TianKang had 12,000 shareholders, an increase of 9.32% from the previous period, with an average of 25,381 circulating shares per person, a decrease of 8.53% [2] - For the period from January to September 2025, TianKang reported a revenue of 526 million yuan, a year-on-year decrease of 8.13%, and a net profit attributable to shareholders of 31.41 million yuan, a decrease of 73.00% [2] - Since its A-share listing, TianKang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [2]
泰恩康10月29日获融资买入1882.34万元，融资余额9.97亿元